Evaluation of a novel eating disorder prevention programme (Australian diabetes body project) for young women with type 1 diabetes in a clinic setting: A randomized controlled trial protocol
Abstract
Background: Co-occurrence of eating disorders (ED) and type 1 diabetes (T1D) can lead to deterioration in glycaemic control with reduced quality of life, microvascular complications, diabetic ketoacidosis and premature death. The current trial aims to test the effectiveness of an Australian Diabetes Body Project (ADBP) programme, a cognitive dissonance-based group intervention, on ED risk factors and symptoms, psychometric analysis, quality of life and glycaemia control in young women with T1D.
Methods: Mixed methods, prospective randomized controlled trial (RCT) using an online, six-week group intervention facilitated by a clinician and a peer with T1D. A sample of 80 young women with T1D aged 15 to 30 years will be randomized to the ADBP or active control (educational videos) condition. Participants will complete assessments of body dissatisfaction, eating behaviours, quality of life and diabetes distress, at baseline, post-intervention and at three-month follow-up. Medical record data will be extracted to determine changes in glycaemia outcomes. ADBP participants will be invited to provide feedback on the benefits and acceptability of the intervention.
Discussion: The ADBP will be the first clinic-based RCT to examine the effectiveness of a virtual, cognitive dissonance-based intervention for reducing ED risk factors and symptoms in young women with T1D. The results of this project will have immediate implications for clinical practice in Australia and globally, given the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.